Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review-Reference-Cited by-同舟云学术

Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review

Published:2021-02-17 Issue:2 Volume:35 Page:175-186
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Chessa Elisabetta^ORCID,Piga Matteo^ORCID,Floris Alberto^ORCID,Congia Mattia^ORCID,Cangemi Ignazio^ORCID,Mathieu Alessandro^ORCID,Cauli Alberto^ORCID

Funder

Università degli Studi di Cagliari

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

http://link.springer.com/content/pdf/10.1007/s40259-021-00467-w.pdf

Reference45 articles.

1. Sepriano A, Kerschbaumer A, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2020;79:760–70. https://doi.org/10.1136/annrheumdis-2019-216653.

2. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685–99. https://doi.org/10.1136/annrheumdis-2019-216655.

3. Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79:700–12. https://doi.org/10.1136/annrheumdis-2020-217159.

4. van der Heijde D, Ramiro S, Landewé R, Baraliakos X, den Bosch FV, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978–91. https://doi.org/10.1136/annrheumdis-2016-210770.

5. Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736–45. https://doi.org/10.1136/annrheumdis-2019-215089.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case report: Crescentic IgA nephropathy with anti‐neutrophil cytoplasmic antibodies, in a patient on golimumab;International Journal of Rheumatic Diseases;2024-09

2. Renal Dysfunction in a Patient With Crohn's Disease During Ustekinumab Treatment: A Case Report and Review of the Literature;Current Therapeutic Research;2024

3. Nefropatía IgA tras tratamiento prolongado con infliximab por enfermedad de Crohn, a propósito de dos casos;Nefrología;2023-02

4. Kidney Effects by Alternative Classes of Medicines in Patients and Relationship to Effects in Nonclinical Toxicity Studies;Toxicologic Pathology;2022-05-24